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Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T cell neoplasm with very poor prognosis.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been reported as a curative treatment
modality for ATL. However, there are no reports comparing chemotherapy alone with allo-HSCT in ATL. In this
report, we retrospectively analyzed data for patients treated with (n ¼ 29, median age 55 years) or without
allo-HSCT (n ¼ 37, median age 58 years) for ATL in Kagoshima University Hospital, located in one of the most
endemic areas of human T cell lymphotropic leukemia virus type 1 infection. Forty patients (61%) started
coordination for allo-HSCT. Ten patients (34.4%) received allo-HSCT while in complete remission (CR), whereas
the others were not in CR. Twenty-ﬁve patients (86.2%) received reduced-intensity conditioning, and the
others receivedmyeloablative conditioning.With amedian follow-up period for survivors of 41months (range,
5 to 125months), the 3-year overall survival (OS) rate from ﬁrst chemotherapy for all patients (with or without
allo-HSCT) was 35.2%. The 3-year OS from ﬁrst chemotherapy for patients who received allo-HSCT or only
chemotherapy was 44.9% and 27.7%, respectively. Univariate analyses revealed that high serum soluble IL-2
receptor (sIL-2R) levels (2000 U/mL) just before the conditioning regimen and progressive disease (PD)
status at HSCT (according to Japan Clinical Oncology Group Study 0907 criteria) were signiﬁcant risk factors for
OS in the allo-HSCT group. Multivariate analyses revealed that PD status was a signiﬁcant risk factor for OS in
the allo-HSCT group. In the chemotherapy-only group, the 3-year OS rate was 61.5% (95% CI, 30.8% to 81.8%) in
patients with serum sIL-2R levels< 2000 U/mL for>3months. In contrast, the 3-year OS rate was 5.7% (95% CI,
.4% to 22.4%) in patients who did not achieve serum sIL-2R levels < 2000 U/mL for >3 months. Our single-
center cohort experience indicates that chemosensitivity is the most important prognostic factor for OS in
ATL patients and the use of allo-HSCT is limited in chemorefractory patients with aggressive ATL disease. In the
chemosensitive patients, allo-HSCT demonstrated a tendency toward better OS. Further clinical studies are
warranted to determine optimal treatments for patients who are less sensitive to conventional chemotherapy.
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ty for Blood and Marrow Transplantation.lymphotropic leukemia virus type 1 (HTLV-1). The prognosis
is very poor, with only a 24% 3-year overall survival (OS) rate
using standard combination chemotherapy [1]. Allogeneic
hematopoietic stem cell transplantation (allo-HSCT) has
been considered a curative treatment modality for those
with aggressive ATL. However, a nationwide retrospective
study demonstrated only a 33% 3-year OS rate [2] in a study
in which some patients did not receive allo-HSCT because of
refractoriness to induction chemotherapy or the patient’s
choice. There is no evidence regarding allo-HSCT in a sample
Table 1
Patient and Transplantation Characteristics in Patients with ATL, Compared Between Treatments
Characteristic Subcharacteristic Allo-HSCT Patients (n ¼ 29) Chemotherapy Only
Patients (n ¼ 37)
Age, yr (range) 55 (32-62) 58 (27-69)
Sex Male 15 (51.7%) 21 (56.8%)
Female 14 (48.3%) 16 (43.2%)
Disease subtype Acute 24 (82.8%) 28 (75.7%)
Lymphoma 5 (17.2%) 9 (24.3%)
Disease status at HSCT (HSCT group)
or initial chemotherapy (chemotherapy-only group)
CR 10 (34.8%) 12 (32.4%)
PR 5 (17.2%) 7 (18.9%)
SD 1 (3.7%)
PD 13 (44.8%) 18 (48.6%)
ATL-PI, mean  standard deviation 3.0  1.4 3.4  1.1
Days from ﬁrst chemotherapy to HSCT Median (range) 204 (90-710)
90 1 (3.7%)
91-180 10 (34.5%)
181 18 (62.1%)
sIL-2R level at HSCT, U/mL 2229 (238-35,125)
Donor MRD 5 (17.2%)
MUD 9 (31.0%)
MMD 15 (51.7%)
Stem cell source BM 14 (48.3%)
PBSC 14 (48.3%)
CB 1 (3.4%)
Conditioning regimen MAC 2 (6.9%)
RIC 27 (93.1%)
TBI Yes 13 (44.8%)
ATG Yes 10 (34.5%)
Flu Yes 24 (82.8%)
Bu Yes 19 (65.5%)
GVHD prophylaxis CSP þ MTX  MMF 10 (35.7%)
TK þ MTX  MMF 18 (64.2%)
MMF Yes 7 (25.0%)
CR indicates complete remission; PR, partial remission; SD, stable disease; PI, prognostic index [16]; MRD, HLA-matched related donor; MUD, HLA-matched
unrelated donor; MMD, HLA-mismatched donor; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning; TBI, total body irradiation; ATG, antithymocyte globulin; Flu, ﬂudarabine; Bu, busulfan; CSP, cyclosporine A; MTX, metho-
trexate; MMF, mycophenolate mofetil; TK, tacrolimus.
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retrospectively analyzed the treatment outcomes of
chemotherapy-only compared with those of chemotherapy
followed by allo-HSCT in ATL patients with aggressive dis-
ease in a single institution.METHODS
Clinical data for 66 patients with aggressive ATL who received chemo-
therapy alone (n ¼ 37) or allo-HSCT (n ¼ 29) for the ﬁrst time between
October 2002 and April 2014 in Kagoshima University Hospital were
retrospectively collected and reviewed. The study protocol was approved by
the institutional review board of Kagoshima University Hospital.
Clinical subtypes of ATL were categorized according to the Shimoyama
criteria [3]. OS was calculated from the day of ﬁrst chemotherapy or HSCT
until death or last observation, as indicated. Patients who remained alive at
the time of the last follow-up were censored. The deﬁnition of a therapeutic
response to HSCT was as previously described, with the following minor
modiﬁcation [4]: The requirement of a 4-week observation period to assess
the therapeutic response before HSCT was not used, and unconﬁrmed
complete remission was not applied because 31% of the allo-HSCT patients
received a preconditioning regimen for allo-HSCT within the 4-week
observation period. Response to treatment was thus divided into 4 cate-
gories [4]: complete remission, partial remission, stable disease, and pro-
gressive disease (PD). Non-PD was deﬁned as complete remission þ partial
remission þ stable disease.Figure 1. Flowchart of study inclusion of ATL patients who received only
chemotherapy or allo-HSCT.Statistical Analysis
Comparisons between the groups were performed using chi-square or
Fisher exact tests for categorical variables, as appropriate, and Mann-
Whitney U tests for continuous variables. The Kaplan-Meier method was
used to estimate OS. The 95% conﬁdence interval (CI) of the 3-year OS was
calculated. The effects of acute graft-versus-host disease (GVHD) (within 60
days after allo-HSCT) on OS were analyzed in patients who achieved
engraftment and survived at least 100 days after transplantation. This
landmark method was used to exclude bias that may have arisen fromincluding patients who died or had a relapse too early to develop GVHD in
the group without GVHD.
The effects of various patient and disease categorical variables on sur-
vival probabilities were examined using the log-rank test, and the following
variables were included in the subgroup analyses: age, sex, serum soluble IL-
2 receptor (sIL-2R) levels at allo-HSCT, donor, stem cell source, and intensity
of the conditioning regimen. Multivariate analysis for OS was performed
using the Cox proportional hazards regression model. All P values were
2-sided, and statistical signiﬁcance was set at P < .05. All statistical analyses
were performed with EZR [5].RESULTS
Patient and Allo-HSCT Characteristics
Twenty-nine ATL patients received allo-HSCT after
chemotherapy (median age, 55 years; range, 32 to 62 years),
and 37 ATL patients received only chemotherapy (median
age, 58 years; range, 27 to 69 years) (Table 1, Figure 1). Three
donors (10.3%) were seropositive for HTLV-1. The peripheral
blood mononuclear cells of these donors were subjected to
Southern blot analysis to examine the monoclonal or
Figure 2. (A) OS after the ﬁrst chemotherapy in patients with ATL. (B) OS in patients receiving either HSCT or chemotherapy only.
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were conﬁrmed as HTLV-1 carriers.
Induction chemotherapy consisted primarily of the VCAP/
AMP/VECP regimen, OPEC/MPEC regimen, or mogamulizu-
mab salvage therapy [6-8] in the allo-HSCT patients, and the
VCAP/AMP/VECP regimen was also the chemotherapy pri-
marily administered in ATL patients who received only
chemotherapy. All but 4 patients received the VCAP/AMP/
VECP regimen [6], administered between 1 and 6 times.
Before the VCAP/AMP/VECP regimen was administered, 21
patients received a CHOP-like regimen [8].
Twenty-seven patients (93.1%) received reduced-
intensity conditioning that consisted of ﬂudarabine with
either busulfan or cyclophosphamide  total body irradia-
tion. The conditioning regimen was chosen by the physician
in each case. Because many of the ATL patients and their
siblings were relatively old, our institute previously con-
ducted clinical trials testing alternative donors from their
sons or daughters [9]; therefore, the percentage of mis-
matched donor selection was high.
Outcomes
Themedian follow-up period for survivorswas 41months
(range, 5 to 125) from the ﬁrst chemotherapy. The 3-year OS
rate and median survival time for the entire cohort (with/
without allo-HSCT) were 35.2% (95% CI, 24.3% to 47.3%) and
437 days (95% CI, 305 to 853 days), respectively (Figure 2A).
The 3-year OS rate for the allo-HSCT and chemotherapy-only
groups were 44.9% (95% CI, 25.4% to 62.6%) and 27.7% (95% CI,
14.0% to 43.2%), respectively (P < .05) (Figure 2B). The 3-year
OS rate for the allo-HSCT group from the time of allo-HSCTFigure 3. (A) OS according to sIL-2R levels in patients with ATL. (B) OS awas 39.9% (95% CI, 20.8% to 58.4%). Three patients with PD
at the timeof allo-HSCTwho received transplantation froman
HTLV-1eseropositive donor died on days 63, 112, and 375,
respectively. Twenty-four patients who achieved neutrophil
engraftment and survived 100 days after allo-HSCT were
assessed for acuteGVHD.Overall, grades II to IV or grades III to
IV acuteGVHDoccurred in 16 (57.1%),14 (50.0%), and 4 (14.3%)
assessable patients. Landmark analysis at day 60 after allo-
HSCT showed the effects of grades II to IV acute GVHD
compared with grades 0 to I acute GVHD on OS (P < .01).
A high sIL-2R level just before preconditioning (2000 U/
mL, P < .01) (Figure 3A) and PD at allo-HSCT (P < .01)
(Figure 3B) were identiﬁed as signiﬁcant risk factors for OS
by univariate analyses. Male sex (P ¼ .10), disease subtype, a
high sIL-2R level at the ﬁrst chemotherapy regimen, ATL
prognostic index  2 [10], HLA mismatch, and the time
before transplantation from ﬁrst chemotherapywere not risk
factors for OS in the allo-HSCT group in the univariate ana-
lyses. The multivariate analysis results showed the PD state
at allo-HSCT was a risk factor for OS in PD patients (hazard
ratio, 4.11; 95% CI, 1.41 to 12.0, P < .01). In patients with PD
after allo-HSCT, 6 patients died of ATL, and 5 patients with
disease progression of ATL died of a transplantation-related
complication. Five other patients died of a transplantation-
related complication while in remission.
Of the 37 patients who received only chemotherapy, 12
patients refused the allo-HSCT even though they were
medically ﬁt, 3 patients had an active infection, 4 patients
had a concurrent or recent solid tumor, 3 patients had other
severe comorbidities, and 15 patients experienced primary
induction failure to conventional chemotherapy. Of the latterfter HSCT, according to disease status (PD versus non-PD at HSCT).
Figure 4. (A) OS according to sIL-2R < 2000 U/ml for >3 months in patients with ATL receiving only chemotherapy. (B) OS in chemosensitive patients with or
without HSCT.
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started the coordination of a donor, but the treating physi-
cian decided against allo-HSCT. Of the 37 patients who
received only chemotherapy, only 15 patients (40.5%) (me-
dian age, 62 years; range, 50 to 68 years) reached serum sIL-
2R levels< 2000 U/mL for>3months, and the 3-year OS was
61.5% (95% CI, 30.8% to 81.8%) (Figure 4). The other 22 pa-
tients had a 3-year OS of 5.7% (95% CI, .4% to 22.4%)
(Figure 4A). The patients in the allo-HSCT group with sIL-2R
levels < 2000 U/mL at HSCT tended to have better OS rates
than the patients in the chemotherapy-only group with sIL-
2R levels < 2000 U/mL for >3 months (Figure 4B, P ¼ .17).DISCUSSION
The 3-year OS rate with allo-HSCT in the present study
was 39.9%. Comparatively, the 3-year OS rate was 33.0% in a
nationwide retrospective study on allo-HSCT for 386 ATL
patients in Japan [2], and a small retrospective analysis on
allo-HSCT for 15 ATL patients reported a 3-year OS rate of
73.3% [11]. Of these 15 patients, only 1 patient had PD at the
time of allo-HSCT, compared with 13 of 29 patients in the
present study. Of the non-PD patients receiving allo-HSCT,
the 3-year OS rate was 60.6% in the present study.
Another nationwide retrospective study on allo-HSCT for
586 ATL patients in Japan demonstrated that disease status at
the time of allo-HSCT (nonecomplete remission) was a sig-
niﬁcant predictor for poorer OS (hazard ratio, 1.94) [12],
indicating that treatment outcome is greatly inﬂuenced by
patient selection. In the present study, a high sIL-2R level just
before preconditioning and PD at HSCT were signiﬁcant risk
factors for OS in the univariate analysis. At the same time, a
3-year OS rate of 78.6% was observed in ATL patients who
received allo-HSCT with low sIL-2R levels just before pre-
conditioning (<2000 U/mL). These results agree with those
of a recent report indicating that high sIL-2R levels at allo-
HSCT are an important risk factor for survival [13]. The
multivariate analysis in the present study conﬁrmed that
patients with non-PD at HSCT were at risk for poorer OS.
Because the sIL-2R levels are strongly correlatedwith disease
status, we did not include sIL-2R levels at allo-HSCT in the
multivariate analysis. However, a high sIL-2R level at allo-
HSCT was determined to be a prognostic factor when used as
an alternative variable for disease status at HSCT in the
multivariate analysis. Thus, sIL-2R levels at allo-HSCT could
be a useful surrogate marker for disease status.
The complex nature of ATL creates challenges for
response assessment. Response criteria for ATL wereproposed at an international consensus meeting [4]; how-
ever, this criteria required a 4-week observation period. In
the present study, 9 of 29 patients received HSCT within 4
weeks after the last chemotherapy, which categorizes the
response criteria as “not assessable.” Objective and less
complex response criteria are required to ensure uniform
interpretation of the results from clinical trials. Because sIL-
2R levels are a good indicator of tumor burden, sIL-2R levels
just before the conditioning regimen could be a better
objective marker for comparing patient backgrounds be-
tween different clinical trials.
Allo-HSCT for those who are chemosensitive (IL-
2R < 2000 U/mL at allo-HSCT) has beenwell established as a
curative therapeutic modality for aggressive ATL; however,
these patients represent only 21% of ATL patients aged <70
years in clinical practice in an ATL-endemic area. Based on
the results of the present study, allo-HSCT might be intro-
duced for patients with serum sIL-2R < 2000 U/mL. The
outcomes of allo-HSCT might be improved with earlier
administration of allo-HSCT in patients with sIL-2R levels
< 2000 U/mL even with alternative donors [9] or mogamu-
lizumab [7] administration before allo-HSCT in patients with
high sIL-2R levels; however, this hypothesis requires testing
in well-designed, prospective trials. Several clinical trials
have investigated the applications of the blocking immune
checkpoint protein, PD-1, by human antibodies; this inter-
action has been validated as an important target for thera-
peutic intervention, termed “immune checkpoint therapy,”
which aims to recover antitumor cytotoxic T lymphocyte
function in advanced cancer patients. We have reported that
HTLV-1especiﬁc cytotoxic T lymphocyte is exhausted with
expression of the immune checkpoint receptors PD-1, 2B4,
and CD160 but was reinvigorated by the blockade of those
receptors [14-16]. These therapies might represent an alter-
native approach to the treatment of ATL in the future.
In clinical practice in an endemic area, allo-HSCT may not
beneﬁt most patients with ATL. Therefore, alternative stra-
tegies need to be explored for chemorefractory ATL patients.ACKNOWLEDGMENTS
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